Physician profile
Hayman Rambaran
NPI 1639295470
$2,073.65
in general payments reported to CMS, 2019-2025
11 companies · $650 in 2025
The $650 reported for 2025 was more than what 82% of Addiction Medicine (Internal Medicine) providers received nationally (typical 2025 total: $124).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $37.45 · 2020: $145 · 2021: $49.07 · 2022: $280 · 2023: $181 · 2024: $731 · 2025: $650.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,562.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,562.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $852.07 | 2020-2025 | Biktarvy, Epclusa |
| Indivior INC. | $343.05 | 2021-2025 | Sublocade |
| Braeburn INC. | $309.38 | 2024-2025 | Brixadi |
| Teva Pharmaceuticals USA, INC. | $174.03 | 2022-2024 | Uzedy, Austedo Xr |
| Neurocrine Biosciences, INC. | $143.39 | 2023-2025 | Ingrezza |
| Astrazeneca Pharmaceuticals Lp | $116.53 | 2020 | |
| Alkermes, INC. | $48.12 | 2020-2025 | Vivitrol |
| Fisher Scientific Company L.L.C. | $37.45 | 2019 | |
| Neuronetics, INC. | $18.43 | 2025 | Neurostar Tms Therapy System |
| Abbvie INC. | $18.00 | 2025 | |
| Janssen Pharmaceuticals, INC | $13.20 | 2023 | Invega Sustenna, Invega, Spravato |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hayman Rambaran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.